| abstract |
A high-affinity IL4 antagonist that suppresses eosinophilic inflammation and can be used for treatment, prevention, or diagnosis of an allergic reaction and use thereof are provided. Complementarity determining regions (CDRs) from non-human neutralizing monoclonal antibodies characterized by a dissociation constant for human interleukin-4 (IL4) equal to or less than 2 × 10 −10 M, and human Alternatively, a fusion protein having binding specificity for human IL4 consisting of a humanized framework structural region. [Selection figure] None |